Skip to main content

Table 2 Ongoing clinical trials with domestic PD-1 or PD-L1 inhibitors on advanced tumors and NSCLC

From: Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Drugs and indentifier

The role of China

Phase

Indication

Design

State

Enrollment

SHR-1210

CTR20160175

Sponsor

I

Advanced solid tumors

Non-randomized, open-label, single-center, dose-escalation

Recruiting

45

SHR-1210

CTR20170090

Sponsor

II S + A

Advanced NSCLC

Non-randomized, open-label, single-center, dose-escalation

Recruiting

118

SHR-1210

CTR20170299

Sponsor

II

Advanced NSCLC

Open-label, single-arm, multicenter

Not yet recruiting

120

SHR-1210

CTR20170322

Sponsor

III S + P + C

Advanced non-squamous NSCLC

Randomized, open-label, multicenter

Not yet recruiting

412

JS-001

CTR20160274

Sponsor

I

Advanced solid tumors

Open-label, single-group assignment

Recruiting

54

IBI308

CTR20160735

Sponsor

I

Advanced malignant tumors

Non-randomized, open-label, single-group assignment

Recruiting

104

BGB-A317

CTR20160872

Sponsor

I

Advanced solid tumors

Non-randomized, open-label, single-group assignment

Not yet recruiting

300

  1. NSCLC non-small cell lung cancer, S + A SHR-1211 plus apatinib, S + P + C SHR-1210 plus pemetrexed and carboplatin